Trelegy is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Trelegy helps prevent bronchospasms.
Trelegy is a combination drug containing fluticasone furoate, umeclidinium, and vilanterol. Fluticasone furoate is a glucocorticoid steroid, a drug that suppresses the immune system. Fluticasone furoate is believed to work by reducing inflammation in the lungs, lowering the risk of bronchospasm. Vilanterol is a long-acting bronchodilator, a drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Vilanterol is believed to work by relaxing smooth muscles in the airways. Umeclidinium, a muscarinic receptor antagonist, is also believed to work by relaxing smooth muscles in the airways.
How do I take it?
Take one inhalation of Trelegy once a day. Trelegy should be taken at the same time each day.
Trelegy comes in an inhaler device.
The FDA-approved label for Trelegy lists common side effects including runny nose, upper respiratory tract infections, flu, headache, back pain, sinus infections, bronchitis, pneumonia, cough, constipation, diarrhea, and urinary tract infections.
Rare but serious side effects listed for Trelegy include problems with the adrenal glands, urinary retention problems, glaucoma, decreased bone density, hypersensitivity reactions, increased risk of infections, and paradoxical bronchospasm (bronchospasm caused by taking medication).
For more details about this treatment, visit:
Trelegy Ellipta — GSK
Fluticasone, Umeclidinium, and Vilanterol Oral Inhalation — MedlinePlus